Disc Medicine (IRON) Expected to Release Earnings on Thursday

Disc Medicine (NASDAQ:IRON) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Disc Medicine to post earnings of ($1.63) per share and revenue of $1.88 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:30 AM ET.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.17. On average, analysts expect Disc Medicine to post ($6.61) EPS for the current fiscal year and ($7.14) EPS for the next fiscal year.

Disc Medicine Stock Up 4.1%

IRON stock opened at $83.20 on Thursday. The stock has a fifty day moving average of $71.28 and a 200-day moving average of $70.74. Disc Medicine has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. The company has a market capitalization of $319.07 million, a price-to-earnings ratio of -12.64 and a beta of 0.93.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on IRON shares. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research report on Thursday, October 15th. Cantor Fitzgerald boosted their price target on Disc Medicine from $125.00 to $170.00 and gave the company an “overweight” rating in a report on Monday, October 19th. BMO Capital Markets raised their price objective on shares of Disc Medicine from $100.00 to $120.00 and gave the stock an “outperform” rating in a report on Monday, October 19th. Wells Fargo & Company upped their price target on Disc Medicine from $86.00 to $124.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 20th. Finally, Truist Financial raised their price target on shares of Disc Medicine from $83.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, October 19th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Disc Medicine presently has an average rating of “Moderate Buy” and an average target price of $122.70.

Insider Activity

In other news, Director Kevin Bitterman sold 25,519 shares of Disc Medicine stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $80.23, for a total value of $2,047,389.37. Following the completion of the transaction, the director owned 12,991 shares in the company, valued at approximately $1,042,267.93. The trade was a 66.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jonathan Yu sold 8,796 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total value of $731,123.52. Following the transaction, the chief operating officer owned 54,324 shares of the company’s stock, valued at $4,515,410.88. This trade represents a 13.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 173,046 shares of company stock worth $13,591,034 over the last quarter. Insiders own 3.76% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company’s pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.